Evotec and Bayer Advance Endometriosis Program into Phase I Clinical Development and Extend Alliance
Evotec also announced today that both companies have agreed to extend this multi-target endometriosis alliance until the end of 2018.
EVOTEC EXPANDS IPSC DRUG DISCOVERY LEADERSHIP THROUGH STRATEGIC COLLABORATION WITH CENSO BIOTECHNOLOGIES
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a collaboration with Censo Biotechnologies Ltd. (“Censo”) to source and provide patient-derived induced pluripotent stem cells (“iPSC”) to support Evotec’s broad iPSC platform. Censo will provide its...